The news from long-suffering biotech Rigel Pharmaceuticals (Nasdaq:RIGL) just continues to get worse. Rigel has already seen AstraZeneca (NYSE: AZN) return the rights to R788, its Syk kinase inhibitor for rheumatoid arthritis, and with Monday's announcement of the failure of R343 in allergic asthma, it's worth asking whether there's any real value left in the company's Syk inhibitor program. Although the company still has a couple of clinical trials ongoing, as well as $250 million in cash, these shares are looking more and more like a spin of the roulette wheel than any sort of real investment opportunity.
Another Syk Failure
Seeing as Rigel's market cap was less than $320 million on Friday, it's difficult to say that the Street had robust expectations for Rigel's Phase II allergic asthma drug R343. While allergic asthma (of varying degrees of severity) affects an estimated 10 million people in the U.S., it's a moot point now as the drug failed to meet both primary and secondary endpoints, leading management to terminate the program. 

SEE: Will Immunotheraphy Disrupt The Oncology Market?

What's Next?
With R343 off the table, attention now shifts to R333, a topical JAK3/Syk inhibitor in a Phase II trial for the treatment of discoid lupus. Discoid lupus is a chronic skin condition that causes inflammation, sores, and scarring of the skin – particularly on the face, ears, and scalp. The musician Seal suffered from this condition earlier in his life, and while it appears to be in remission now it caused significant facial scarring and hair loss.
The market potential of an effective treatment for discoid lupus is likely worthwhile, as there are more than 50,000 people in the U.S. estimated to have this condition. That potential may be moot, though, as the company's failures thus far in developing effective Syk inhibitors raises the question of whether they really have a firm understanding of the relevant mechanism(s) of action and the resulting ability to design effective drugs.
Rigel also has R348 in clinical development as a treatment for dry eye. Given how difficult this condition is to treat, Allergan's (NYSE:AGN) Restasis is the only approved drug specifically targeting this indication, R348 has to be considered a long-shot at best.
Still Awaiting Word On R788
Rigel has yet to make a final determination of its plans for R788 (aka fostamatinib), the oral Syk kinse inhibitor it has explored for the treatment of rheumatoid arthritis. After a largely disappointing clinical development history, AstraZeneca opted to return this drug to Rigel and walk away from the partnership.
Although R788 has shown some signs of efficacy, and could theoretically have a role in patients who fail DMARD therapy, I think you have to consider AstraZeneca's own desperation for growth when evaluating the potential of R788 – if there were any serious, credible market opportunity for R788, I highly doubt AstraZeneca would have abandoned it. That said, Rigel could still elect to try to submit an NDA, at which point the company would still need to find a marketing partner for a drug whose clinical data package suggests that a major marketing effort would be needed to generate meaningful sales.
The Bottom Line
Rigel shares are trading at about 15% to 20% above cash value per share, and I think that's a fair price considering the circumstances. The company has yet to demonstrate that it has a commercially viable product candidate in its pipeline, and pursuing a Phase III study for either discoid lupus or dry eye could well consume half (or more) of the current cash balance. Given the paucity of data on either of those drugs, buying Rigel today is basically just a nearly blind bet on one or both of those Phase II trials delivering positive data. That's gambling, not investing, and I don't see a compelling reason to bother with Rigel shares today.
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Investing News

    Will Immunotherapy Disrupt The Oncology Market?

    Immunotherapy could radically change the treatment of cancer, and the revenue opportunities for pharmaceutical companies.
  2. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  3. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  4. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  5. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  6. Stock Analysis

    Forest Laboratories: An Activist Investment Analysis

    Find out how patience and perseverance paid off big-time for billionaire activist Carl Icahn during his four-year fight with Forest Laboratories.
  7. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  8. Investing News

    Zika: Study Says This Device Could Protect You

    New research just uncovered an inexpensive, commercially available device that might help fight off the mosquito that carries the dreaded Zika virus.
  9. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  10. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center